Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
In Europe, treatment of metastatic colorectal cancer (mCRC) with panitumumab requires prior confirmation of RAS wild-type mutation status. Two studies – a physician survey and a medical records review (MRR) – were conducted to evaluate the use of panitumumab and awareness among prescribing oncologists of the associated RAS testing requirements in clinical practice. | Panitumumab use in metastatic colorectal cancer and patterns of RAS testing Results from a Europe-wide physician survey and medical records review
